



HIV Treatment and Cure Research Highlights at AIDS 2024

Here is a preview of HIV treatment and cure research highlights you can expect.

June 26, 2024 By [International AIDS Society](#)

In less than a month, thousands of people will gather at AIDS 2024, [the 25th International AIDS Conference](#), in Munich, Germany, and virtually to share knowledge, best practices and lessons learnt from the HIV response. Here is a preview of HIV treatment and cure research highlights you can expect.

[Register today](#) for AIDS 2024 from 22 to 26 July.

Some HIV treatment and cure research highlights to expect at AIDS 2024

- An update from the ARTISTRY-1 study, which is evaluating bictegravir plus lenacapavir in virologically suppressed people with HIV who are otherwise unable to take a single-tablet regimen
- An analysis of emerging dolutegravir resistance in children and adolescents living with HIV in Malawi
- Extended week 96 analysis data from the D²EFT trial on the extended efficacy and safety of dolutegravir- and darunavir- containing regimens
- A study showing that PD-1 blockade combined with therapeutic vaccination leads to sustained suppression of SIV following ART discontinuation in macaques
- A novel approach to treat HIV reservoirs in gut-associated lymphoid tissues using nanoformulations of combination antiretroviral therapy drugs

AIDS 2024 late-breaker abstracts are now also available in the [programme](#).
